Fidelity and Vanguard both offer relatively limited rosters of dividend exchange-traded funds (ETFs). Both are winners for different reasons, but each of their dividend ETFs has some flaws.
Zimmer Biomet has trailed the broader market over the past year, and it continues to face skeptical sentiment from analysts regarding its near- to medium-term growth outlook.
T. Rowe Price’s fourth quarter results were met with a significant negative reaction from the market, reflecting disappointment over the company’s inability to meet Wall Street’s top- and bottom-line expectations. Management attributed the quarter’s performance to elevated redemptions, particularly in its equity and mutual fund businesses, despite strong global market returns. CEO Robert Sharps acknowledged that net outflows and persistent industry-wide shifts toward lower-fee products affected the company’s asset mix and fee rates, noting, “We saw an increase in gross sales, which were higher than 2024 and up over 40% from 2023, but redemptions were greater than anticipated.” Sharps also cited weaker performance in certain strategies and client portfolio rebalancing as drivers of the outflows and margin pressure.
Our top chart strategist explains what sets apart the best software stocks, and how investors can buy shares at a discount while volatility is still high.
The Vanguard Consumer Staples ETF and the Invesco Food & Beverage ETF both promise defensive exposure, but they approach it through different strategies. This comparison explains how those design choices affect cost and the kind of stability investors can realistically expect.
/AI%20(artificial%20intelligence)/OpenAI%2C%20Stability%20AI%2C%20AI21%20Labs%2C%20Anthropic%2C%20and%20Deepmind%20logos%20are%20seen%20on%20their%20websites%20on%20a%20computer%20by%20Tada%20Images%20via%20Shutterstock.jpg)
